Epigenomics is developing oncology diagnostics based on DNA methylation patterns. The company has launched two diagnostics: a blood test for early detection of colorectal cancer is available in the US, Europe, Asia/Pacific and Canada and a bronchial lavage test for the detection of lung cancer is available in Europe. Epigenomics is a VIPE (Venture Investment in Public Equity).